Genmab — Maj 2024
-
Epcoritamab and Rybrevant on the EMA agenda this week. Also Tisotumab on Initial applications; List of questions (Day 120; Day 90 for
procedures with accelerated assessment timetable); so i guess that means they got accelerated assessment? (as the applicatoin was validated in Feb) https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-27-30-may-2024_en.pdf -
at least someone has epco in their list of top ASCO abstracts
- Hematologic Malignancies ASCO 2024 Preview - https://www.delveinsight.com/asco-conference/article/hematologic-malignancies-preview-asco-2024?utm_source=asco&utm_medium=promotion&utm_campaign=kpr -
Acasunlimab starting on the EMEA treadmill on the Paediatric Committee (PDCO)
Agenda https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-28-31-may-2024-meeting_en.pdf -
Nummer 10 hvis man fraregner covid
-
Nummer 3 er en anden dansker. Ozempic. Den når meget tæt på 1. pladsen i år. Næste år meget klar 1. plads med den første non covid til at runde $30 mia og $40 mia
-
Genmab updated it's website to include ProfoundBio, including the pipeline https://www.genmab.com/antibody-science/pipeline
-
-
Video: Den Europæiske Centralbank ECB sætter formentlig renten ned i næste uge, men hvor meget? Hør også om NVIDIA, Mærsk og DSV's interesse for at købe DB Schenker, samt om de to danske biotekselskaber Zealand Pharma, Novo Nordisk og Genmab. https://proinvestor.com/boards/120672
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind